Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it

A technology of composition and crystal form, applied in the field of new crystal form III of N-[2-ethyl]acetamide, capable of solving problems without specific instructions

Inactive Publication Date: 2007-02-07
LES LAB SERVIER
View PDF1 Cites 64 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the document does not specify the conditions under which agomelatine exhibiting these properties can be obtained in a reproducible manner

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
  • New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Form III of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide

[0018] 2θ angle (°)

Embodiment 2

[0019] Embodiment 2: pharmaceutical composition

[0020] Prepare a prescription for 1000 tablets, each containing a 25mg dose:

[0021] The compound of Example 1……………………………… 25g

[0022] Lactose monohydrate…………………………………………… 62g

[0023] Magnesium stearate…………………………………………… 1.3g

[0024] Corn starch…………………………………………………………… 26g

[0025] Maltodextrin mixture……………………………………9g

[0026] Anhydrous colloidal silicon dioxide……………………………………… 0.3g

[0027] Sodium Starch Glycolate Type A………………………………… 4g

[0028] Stearic acid……………………………………………………… 2.6g

Embodiment 3

[0029] Embodiment 3: pharmaceutical composition

[0030] Prepare a prescription for 1000 tablets, each containing a 25mg dose:

[0031] The compound of Example 1……………………………… 25g

[0032] Lactose monohydrate…………………………………………… 62g

[0033] Magnesium stearate…………………………………………… 1.3g

[0034] Povidone……………………………………………………9g

[0035] Anhydrous colloidal silicon dioxide……………………………………… 0.3g

[0036] Sodium carboxymethylcellulose………………………………………………………………………………………………………30g

[0037] Stearic acid……………………………………………………… 2.6g

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The crystalline form III of a compound of formula (I) is characterised by the X diffraction diagram thereof on a powder, and the drugs contains it.

Description

technical field [0001] The present invention relates to the new crystal form III of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I): [0002] [0003] Its preparation method and pharmaceutical composition containing it. Background technique [0004] Agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, has valuable pharmacological properties. [0005] It does have a dual profile, on the one hand, it is an agonist of receptors of the melatonergic system, on the other hand, it is a 5-HT 2C receptor antagonists. These properties make it active in the central nervous system, more particularly in severe depression, seasonal affective disorder, sleep disturbances, cardiovascular diseases, digestive disorders, insomnia and fatigue due to jet lag, appetite disturbances active in the treatment of obesity. [0006] Agomelatine, its preparation and its therapeutic use are described in European patent specification EP 0 447 285 . [0007] In view o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C233/18A61K31/165A61P25/00A61P25/24A61P25/18A61P9/00A61P1/00A61P25/20A61P3/04
CPCC07C231/24C07C233/18C07C2102/10C07C2602/10A61P1/00A61P15/00A61P15/08A61P17/00A61P25/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28A61P3/00A61P3/10A61P35/00A61P3/04A61P37/00A61P43/00A61P5/06A61P9/00
Inventor G·科克雷尔J·里诺尔J-C·苏维
Owner LES LAB SERVIER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com